[Rise in serum creatinine under the androgen fluoxymesterone in chronic renal disease (author's transl)].
Eight men with chronic renal disease in the stage of compensated retention were given high doses of the androgen fluoxymesterone (40 mg/m2/day) for erythropoietin stimulation for 4 weeks. Seven of them showed a transient significant average rise in the serum creatinine level of 3.8 to 6.1 mg% which partly regressed only 8 to 12 weeks after stopping the medication. The rise in serum creatinine which appears under fluoxymesterone is attributable to a transient increase in the renal excretory function disturbance and/or a raised catabolism. Warning should be given against the further use of this drug in the treatment of renal anemia.
D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy; D003404:Creatinine / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005474:Fluoxymesterone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D012737:Sex Factors; D014511:Uremia / Q000139:chemically induced
D005474:Fluoxymesterone; D003404:Creatinine
Serum- Kreatininanstieg bei chronisch Nierenkranken unter dem Androgen Fluoxymesteron